ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NIVF vs MGRX // ENTERPRISE SCALE & MARKET CAP

NewGenIvf Group Limited (Class A) (NASDAQ) VS. Mangoceuticals Inc. (NASDAQ) • 15-METRIC TALLY: NIVF 5 — MGRX 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: NIVF
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NIVF VS. MGRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NIVF MGRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 54.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.80% -35.00% +2.20 NIVF /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin 68.00% -60.00% +128.00 NIVF /net-margins <GO>
Revenue Growth (YoY) -13.00% -26.00% +13.00 NIVF /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.63 0.20 +0.43 NIVF /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 22.5 32.1 -9.55 MGRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $11.3M $5.7M $5.6M NIVF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NIVF REV MGRX REV NIVF GROSS % MGRX GROSS % NIVF FCF MGRX FCF
FY 2025 $4.7M $456.0K 20.2% 54.9% -$11.1M -$5.9M
FY 2024 $5.4M $615.9K 33.6% 61.7% -$8.3M -$4.9M
FY 2023 $5.1M $731.5K — — -$1.8M -$7.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NIVF // BETA —
MGRX // BETA —